GYRE Stock Price Chart
GYRE Earnings
Gyre Therapeutics Inc
$7.47
5.65%
$0.39
At close: May 08, 16:00:00 GMT-4
$7.1
-4.95%
$-0.37
Post-market: May 08, 20:00:00 GMT-4
Back
Gyre Therapeutics Inc (GYRE) Earnings
Key Stats
Prev.Close
$7.07
Open
$7.21
Day's Range
$7.1 - $7.47
52 week range
$6.57 - $11.78
Volume
51.5K
Avg.Volume
93.0K
Dividend yield
--
EPS (TTM)
0.05
Market Cap
$648.3M
What is GYRE?
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 574 full-time employees. The company went IPO on 2006-04-12. The firm is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. The company is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. The company is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. The company is also focused on commercializing the avatrombopag product.
